TBC1D2B

Across TCGA pan-cancer cohorts, TBC1D2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TBC1D2B data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TBC1D2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D2B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, LGG, and SKCM are the cancer types where TBC1D2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.553	0.764	.001	16	view →
LGG	DFS	Median	All	0.083	0.833	<.001	12	view →
SKCM	DFS	Median	II,III,IV	0.810	0.542	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TBC1D2B–LUSC (OS)

Open the LUSC breakdown →